Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 3,316 restricted stock units (RSUs) to five newly-hired employees as of February 28, 2025.
The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting on each anniversary of the Grant Date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
The RSUs include an acceleration clause that allows for immediate full vesting if the employee's employment is terminated for 'good reason' or without 'cause' within one year of a change in control event.
Karyopharm Therapeutics (Nasdaq: KPTI), un'azienda farmaceutica in fase commerciale focalizzata su terapie innovative per il cancro, ha annunciato l'assegnazione di 3.316 unità di azioni vincolate (RSU) a cinque nuovi dipendenti a partire dal 28 febbraio 2025.
Le assegnazioni di RSU, concesse nell'ambito del Piano di Incentivazione alle Azioni di Induzione 2022 dell'azienda, matureranno in tre anni, con il 33 1/3% che matura ogni anniversario della Data di Assegnazione. Le concessioni sono state effettuate in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivi all'assunzione.
Le RSU includono una clausola di accelerazione che consente la maturazione immediata totale se il rapporto di lavoro del dipendente viene interrotto per 'buona causa' o senza 'giusta causa' entro un anno da un evento di cambiamento di controllo.
Karyopharm Therapeutics (Nasdaq: KPTI), una empresa farmacéutica en etapa comercial centrada en terapias innovadoras contra el cáncer, ha anunciado la concesión de 3,316 unidades de acciones restringidas (RSUs) a cinco empleados recién contratados a partir del 28 de febrero de 2025.
Las asignaciones de RSU, otorgadas bajo el Plan de Incentivo de Acciones de Inducción 2022 de la Compañía, se consolidarán en tres años, con el 33 1/3% consolidándose en cada aniversario de la Fecha de Concesión. Las concesiones se realizaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como incentivos de empleo.
Las RSUs incluyen una cláusula de aceleración que permite la consolidación total inmediata si el empleo del empleado se termina por 'buena razón' o sin 'causa' dentro de un año de un evento de cambio de control.
Karyopharm Therapeutics (Nasdaq: KPTI), 혁신적인 암 치료에 중점을 둔 상업 단계의 제약 회사가 2025년 2월 28일부터 새로 고용된 다섯 명의 직원에게 3,316개의 제한 주식 단위(RSU)를 부여했다고 발표했습니다.
이 RSU 보상은 회사의 2022 유도 주식 인센티브 계획에 따라 부여되며, 3년 동안 분할 지급됩니다, 부여일의 매년 anniversary마다 33 1/3%가 지급됩니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인으로 이루어졌습니다.
RSU에는 직원의 고용이 '정당한 사유'로 종료되거나 '사유 없이' 통제 변경 사건 발생 후 1년 이내에 종료될 경우 즉시 전액 지급되는 가속 조항이 포함되어 있습니다.
Karyopharm Therapeutics (Nasdaq: KPTI), une entreprise pharmaceutique en phase commerciale axée sur de nouvelles thérapies contre le cancer, a annoncé l'attribution de 3 316 unités d'actions restreintes (RSUs) à cinq nouveaux employés à partir du 28 février 2025.
Les attributions de RSU, accordées dans le cadre du Plan d'Incitation aux Actions de 2022 de la société, seront acquises sur trois ans, avec 33 1/3 % acquérant chaque anniversaire de la Date d'Attribution. Les attributions ont été effectuées conformément à la Règle de Cotation Nasdaq 5635(c)(4) en tant qu'incitations à l'emploi.
Les RSU comprennent une clause d'accélération qui permet une acquisition totale immédiate si l'emploi de l'employé est résilié pour 'bonne raison' ou sans 'cause' dans l'année suivant un événement de changement de contrôle.
Karyopharm Therapeutics (Nasdaq: KPTI), ein pharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf neuartige Krebstherapien konzentriert, hat die Gewährung von 3.316 eingeschränkten Aktieneinheiten (RSUs) an fünf neu eingestellte Mitarbeiter ab dem 28. Februar 2025 bekannt gegeben.
Die RSU-Zuweisungen, die im Rahmen des Unternehmensplans für Anreizaktien 2022 gewährt wurden, werden über drei Jahre fällig, wobei 33 1/3 % an jedem Jahrestag des Gewährungsdatums fällig werden. Die Zuteilungen erfolgten gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Beschäftigungsanreize.
Die RSUs enthalten eine Beschleunigungsklausel, die eine sofortige vollständige Fälligkeit ermöglicht, wenn das Arbeitsverhältnis des Mitarbeiters aus 'gutem Grund' oder ohne 'Ursache' innerhalb eines Jahres nach einem Kontrollwechselereignis beendet wird.
- None.
- None.
Each RSU award will vest over three years, with 33 1/
In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302388706.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
How many RSUs did Karyopharm Therapeutics (KPTI) grant to new employees in February 2025?
What is the vesting schedule for KPTI's February 2025 RSU grants?
What happens to KPTI's RSU grants in case of a change in control event?
Under which plan were the February 2025 KPTI RSU grants issued?
